Biomarin Pharmaceuticals (BMRN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2024 | 09-2024 | 06-2024 | 03-2024 | 12-2023 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 942,842 | 675,448 | 972,150 | 746,996 | 755,127 |
| Marketable Securities | 194,864 | 254,996 | 252,201 | 299,584 | 318,683 |
| Receivables | 660,535 | 777,547 | 691,232 | 637,163 | 633,704 |
| Inventories | 1,232,653 | 1,179,339 | 1,183,621 | 1,137,982 | 1,107,183 |
| Other current assets | 201,533 | 169,260 | 160,426 | 163,287 | 141,391 |
| TOTAL | $3,232,427 | $3,056,590 | $3,259,630 | $2,985,012 | $2,956,088 |
| Non-Current Assets | |||||
| PPE Net | 1,043,041 | 1,045,408 | 1,052,898 | 1,060,425 | 1,066,133 |
| Investments And Advances | 521,238 | 561,985 | 557,083 | 620,551 | 611,135 |
| Intangibles | 451,477 | 457,119 | 461,732 | 475,852 | 490,900 |
| Other Non-Current Assets | 1,740,757 | 1,730,093 | 1,735,778 | 1,730,833 | 1,717,347 |
| TOTAL | $3,756,513 | $3,794,605 | $3,807,491 | $3,887,661 | $3,885,515 |
| Total Assets | $6,988,940 | $6,851,195 | $7,067,121 | $6,872,673 | $6,841,603 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | N/A | N/A | 494,837 | 494,357 | 493,877 |
| Accounts payable and accrued liabilities | 606,988 | 715,658 | 572,500 | 593,543 | 683,147 |
| TOTAL | $606,988 | $715,658 | $1,067,337 | $1,087,900 | $1,177,024 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 723,962 | 722,141 | 713,485 | 710,957 | 713,030 |
| TOTAL | $723,962 | $722,141 | $713,485 | $710,957 | $713,030 |
| Total Liabilities | $1,330,950 | $1,437,799 | $1,780,822 | $1,798,857 | $1,890,054 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 190,777 | 190,583 | 190,383 | 189,880 | 188,676 |
| Common Shares | 191 | 191 | 190 | 190 | 189 |
| Retained earnings | -194,695 | -319,638 | -425,718 | -532,892 | -621,554 |
| Other shareholders' equity | 50,426 | -7,067 | 15,126 | -12,746 | -38,648 |
| TOTAL | $5,657,990 | $5,413,396 | $5,286,299 | $5,073,816 | $4,951,549 |
| Total Liabilities And Equity | $6,988,940 | $6,851,195 | $7,067,121 | $6,872,673 | $6,841,603 |